Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O60885: Variant p.Tyr430Cys

Bromodomain-containing protein 4
Gene: BRD4
Feedback?
Variant information Variant position: help 430 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Tyrosine (Y) to Cysteine (C) at position 430 (Y430C, p.Tyr430Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (Y) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CDLS6; likely pathogenic; reduced acetylated histone binding. Any additional useful information about the variant.


Sequence information Variant position: help 430 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1362 The length of the canonical sequence.
Location on the sequence: help REYRDAQEFGADVRLMFSNC Y KYNPPDHEVVAMARKLQDVF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         REYRDAQEFGADVRLMFSNCYKYNPPDHEVVAMARKLQDVF

Mouse                         REYRDAQEFGADVRLMFSNCYKYNPPDHEVVAMARKLQDVF

Zebrafish                     RQYREAQEFAADVRLMFSNCYKYNPPDHEVVAMARKLQDVF
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1362 Bromodomain-containing protein 4
Domain 348 – 457 Bromo 2
Site 433 – 433 Acetylated histone binding
Mutagenesis 433 – 433 N -> A. Abolishes binding to acetylated histones.
Helix 415 – 432



Literature citations
BRD4 interacts with NIPBL and BRD4 is mutated in a Cornelia de Lange-like syndrome.
Olley G.; Ansari M.; Bengani H.; Grimes G.R.; Rhodes J.; von Kriegsheim A.; Blatnik A.; Stewart F.J.; Wakeling E.; Carroll N.; Ross A.; Park S.M.; Bickmore W.A.; Pradeepa M.M.; FitzPatrick D.R.;
Nat. Genet. 50:329-332(2018)
Cited for: VARIANT CDLS6 CYS-430; CHARACTERIZATION OF VARIANT CDLS6 CYS-430; INVOLVEMENT IN CDLS6; FUNCTION;
Understanding the new BRD4-related syndrome: Clinical and genomic delineation with an international cohort study.
Jouret G.; Heide S.; Sorlin A.; Faivre L.; Chantot-Bastaraud S.; Beneteau C.; Denis-Musquer M.; Turnpenny P.D.; Coutton C.; Vieville G.; Thevenon J.; Larson A.; Petit F.; Boudry E.; Smol T.; Delobel B.; Duban-Bedu B.; Fallerini C.; Mari F.; Lo Rizzo C.; Renieri A.; Caberg J.H.; Denomme-Pichon A.S.; Tran Mau-Them F.; Maystadt I.; Courtin T.; Keren B.; Mouthon L.; Charles P.; Cuinat S.; Isidor B.; Theis P.; Mueller C.; Kulisic M.; Tuerkmen S.; Stieber D.; Bourgeois D.; Scalais E.; Klink B.;
Clin. Genet. 102:117-122(2022)
Cited for: VARIANTS GLY-145; 235-GLN--PHE-1362 DEL; PRO-295 AND CYS-390; VARIANT CDLS6 CYS-430; INVOLVEMENT IN CDLS6;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.